Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pulmonx ( (LUNG) ) has issued an update.
On May 22, 2025, Pulmonx Corporation held its 2025 Annual Meeting of Stockholders, where approximately 82.79% of the company’s shares were represented. During the meeting, stockholders elected three Class II directors, ratified the appointment of BDO USA, P.C. as the independent accounting firm for 2025, and approved executive compensation on a non-binding advisory basis.
The most recent analyst rating on (LUNG) stock is a Hold with a $4.15 price target. To see the full list of analyst forecasts on Pulmonx stock, see the LUNG Stock Forecast page.
Spark’s Take on LUNG Stock
According to Spark, TipRanks’ AI Analyst, LUNG is a Neutral.
Pulmonx’s stock score reflects strong revenue growth and gross margins but is heavily weighed down by ongoing financial losses and negative cash flows. Technical indicators suggest bearish momentum, and a negative P/E ratio underscores valuation concerns. While international growth is a positive highlight, the financial and operational challenges weigh significantly on the overall score.
To see Spark’s full report on LUNG stock, click here.
More about Pulmonx
Pulmonx Corporation operates in the healthcare industry, focusing on medical technology. The company specializes in developing and commercializing minimally invasive treatments for patients with lung diseases, with a particular emphasis on emphysema.
Average Trading Volume: 359,173
Technical Sentiment Signal: Sell
Current Market Cap: $125.6M
For an in-depth examination of LUNG stock, go to TipRanks’ Stock Analysis page.